Nearly 36 million people worldwide are afflicted with Alzheimer's disease today. Every 68 seconds someone in the U.S. develops Alzheimer's.
In 2012 alone, the direct costs of Alzheimer's in America will total an estimated $200 billion. By 2050, these numbers will triple.
There are currently no drugs to treat or cure Alzheimer's. For every $28,000 spent on Alzheimer's patient care, only $100 is spent on research. The cost of this disease is not matched by research funding. There is only $480 million of NIH research funding dedicated to Alzheimer's, compared to $6 billion for Cancer, $4 billion for Heart Disease and $3 billion for HIV / AIDS.
The Alzheimer's Drug Discovery Foundation uses strategies of venture capital investing to identify, fund, and advance the most promising Alzheimer’s research, particularly programs in the early stages of drug development that do not yet have significant industry or investor support.
Help the Alzheimer's Drug Discovery Foundation (ADDF) fight to conquer Alzheimer's through drug development by making a donation to fund a scientist!
The ADDF's biomedical venture philanthropy model is working. In spring 2012, the FDA approved Amyvid™, the first diagnostic test for Alzheimer’s and other causes of cognitive decline. The ADDF provided the critical seed funding for early research at the University of Pennsylvania that led to the diagnostic’s development and approval.
Your support will help us continuing our fight to find a treatment or cure for Alzheimer's Disease!
Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.
To date, the ADDF has invested more than $60 million to fund ~400 drug research programs at academic centers and biotechnology companies in 18 countries.
100% percent of funds raised by the ADDF are used to support Alzheimer’s drug research and related programs.